Treatment of intractable seizures other than spasms is difficult and controversial. There are few studies on efficacy of adrenocorticotropic hormone (ACTH) in treatment of patients with intractable seizure.
Materials & Methods
Twenty-five patients with intractable seizure other than spasm including 14 boys and 11 girls with median age of 58 months referred to university clinics of Pediatric Neurology in Isfahan, Iran, during 2014-2015 were prospectively investigated. ACTH was administrated according to our protocol. All cases were followed regularly and assessed for response to treatment and probable side effects, 3 wk after beginning of ACTH therapy and three months after the ACTH therapy. EEG finding were recorded before and three months after the end of ACTH therapy. Statistical analysis using Freidman test and Wilcoxon signed -rank test were performed in order to compare seizure frequency and EEG changes, respectively.
results
Mean A significant reduction (>80%) in seizure frequency in 11 cases (44%) and moderate reduction (50%-80%) in 7 (28%) after 3 wk of ACTH therapy. Despite initial positive response, recurrence of seizure was observed in 7 out of 18 cases with favorable initial response within 3 months after ACTH therapy cessation. The comparison of EEG finding before and 3 months after ACTH therapy using Wilcoxon signed -rank test showed significant differences .
Conclusion
ACTH therapy may be useful in treatment of children with intractable seizures who are resistant to usual antiepileptic drugs. However further studies should be performed to determine the long-term efficacy of ACTH in treatment of intractable seizure.
Keywords: ACTH; Children; Epilepsy; Seizures; Intractable
OrigiNal arTiCle introduction
Epilepsy and epileptic syndromes are a heterogeneous group of conditions with a prevalence of 5.3-8.8 per 1000 in children below 13 yr of age (1, 2) . Overall, 20%-25% of epileptic patients are resistant to all classical antiepileptic drugs. An intractable seizure is defined by therapeutic failure of seizure freedom in response to two tolerated and appropriately chosen antiepileptic drugs at reasonable doses. enrolled into this study. Inclusion criteria were as follows: Age 1 month-14 yr; severe intractability; severely abnormal EEG; absence of contraindication for ACTH (renal failure, hypertension, cardiac failure, serious infection, peptic ulcer disease, diabetes mellitus...); and Close follow-up. Exclusion criteria were severe complication to ACTH: hyperglycemia, hypertension, serious infection; loss of close follow-up; Infantile spasm; and partial seizures with no accompanying generalized seizure. Seizure frequency was recorded for a period of 2 wk by patient's parents before initiation of treatment with ACTH. For all patients, EEG was recorded before treatment. They received ACTH therapy with synacthen ampule 1mg/1 ml, according to our protocol consisted the dose of 25mcg/kg/day for duration of one week, 12.5 mcg/ kg/day for three days, 12.5 mcg /kg every other day for 4 d, 12.5 mcg/kg every week for duration of 4 wk and 6 mcg/kg every week for duration of 4 wk. Standard treatment with anticonvulsants continued during period of treatment with ACTH for all patients. All of the cases were followed regularly in Subspecialty Clinic of Pediatric Neurology and evaluated for seizure control and probable side effects. Laboratory tests for probable side effects including Na, K, BS, BUN, Cr, Ca, p, alp, CBC, ESR, CRP was performed 3, 7, 14 d after beginning of treatment. EEG finding were recorded before, after termination of ACTH therapy and three months later. All 25 cases had intractable seizure with multiple daily recurrence and severely abnormal EEG before ACTH therapy. Clinical features of patients including sex, age at onset of seizure, developmental status, and etiology of epilepsy, MRI findings and prior history of west syndrome are shown in Table 1 . After ACTH, therapy patients were categorized into four groups according to their response to treatment. Group 1 with excellent response (more than 80% reduction in seizure frequency), group 2 with moderate response (50%-80% reduction in seizure frequency), group 3 with mild response (20%-50% reduction in seizure frequency) and group 4 with minimal response or no response. EEG recording was performed in all cases before and Frequency of seizures and duration of non-controlled epilepsy was considered as criteria for intractable seizure (1, 3) . Although corticosteroids and adrenocorticotropic hormone (ACTH) as a treatment option are used in different epilepsies and epileptic syndromes, the efficacy of ACTH and steroids in controlling intractable seizure other than spasms has been studied only in few studies (4) (5) (6) (7) (8) . ACTH therapy is also effective for epilepsies other than infantile spasm (6, (9) (10) (11) (12) (13) . In this article, we report our experience using ACTH in the treatment of 25 patients with generalized seizures other than spasms who had been refractory to all usual AEDs.
Materials & Methods
Twenty-five patients with intractable seizure other than spasm including 14 boys and 11 girls with median age of 58 months referred to university clinics of pediatric neurology in Isfahan, Iran, during 2014-2015 were prospectively investigated in this study. The protocol of the study was approved by the Paediatrics Review Board and the Regional Ethics Committee of Isfahan University of Medical Sciences (Research Project Number: 394156). Written informed consent was obtained from the parents of selected patients after describing the goal of and treatments in the study. Their seizures were refractory to all appropriate antiepileptic drugs including valproate, levetiracetam, ethosuximide, topiramate, lamotrigine, clonazepam, clobazam, nitrazepam, zonisamide, and acetazolamide. In six cases, ketogenic diet had been tried with no therapeutic effect. These patients had shown no effective response to combination therapy of at least two of these drugs before ACTH administration. In this study design, the arbitrary phrase "multiple daily recurrences" was defined as more than ten episodes of seizures per week. Severely intractable epilepsy was defined as multiple daily recurrences and no response to all appropriate anticonvulsants. Severely abnormal EEG was defined as EEGs with more than 80% of tracing being covered with epileptic discharges. The patient with multiple daily recurrences and no response to all appropriate anticonvulsants were for antiepileptic action of ACTH; however, the precise mechanism is not fully understood. ACTH acts as a neuropeptide within the brain and it directly may have anti-convulsive properties (14) . It also stimulates the synthesis of two allosteric modulators of GABA-A receptors including deoxycorticosterone and tetrahydroxy-corticosterone (15) . ACTH has been demonstrated to down-regulate the expression of corticotrophin-releasing hormone (CRH) which results in reduction of pro convulsant activity in the developing brain (16) . In addition, ACTH may stimulate glucocorticoid synthesis. Interaction of glucocorticoid with central nervous system steroid receptors is supposed to influence voltage-dependent calcium channels (17) . Totally, 72% of patients achieved favorable response (>50% reduction of seizure frequency) in short-term to ACTH therapy. Follow-up of the patients, 3 months after stopping ACTH therapy, showed recurrence of seizure in 38% of early responders. The excellent effectiveness of ACTH in treatment of infantile spasm but there are only a few studies on effectiveness of ACTH in treatment of patients with intractable seizure other than spasm. Snead et al. described their experience of treatment of intractable seizure other than spasms with prednisolone or ACTH. In their study, successful cessation of seizure was achieved in 74% of patients ACTH therapy and in none of the patients treated with prednisolone (5). Sinclair used prednisone for treatment of 28 cases with intractable epilepsy. During follow-up period of 1 to 5 yr, 46% of the patients became seizure free and significant decrease in seizure frequency was observed in 40% (18) . Steroids were administrated on the treatment of epilepsy beyond infantile spasm in 32 children with intractable seizure. In a study, 25% cases became seizure free, 11% had a seizure reduction of >50% and 11% had a seizure reduction of <50% (7) . Fifteen children were studied with intractable seizure other than spasm. The seizure was controlled in 13 cases by ACTH therapy but recurrence of seizures was observed in 6 of them within 3 months after stopping ACTH therapy (6) . Successful use of ACTH was described in two patients with generalized epilepsy who had refractory to multiple AED (13 
results
Responses to ACTH therapy were evaluated 3 wk after initiation and 3 months after cessation of ACTH therapy ( Table 2 ). Among 25 patients who had intractable seizure with multiple daily recurrences before ACTH therapy, 18 cases showed more than 50% reduction in seizure frequency 3 wk after initiation of ACTH therapy. However, in 7 of 18 cases (38%), relapse of seizures was observed within 3 months after end of ACTH therapy. Four of eleven cases with excellent response (more than 80% reduction in seizure frequency) and 3 of 7 cases with moderate response (50%-80% reduction in seizure frequency) showed relapse of seizures 3 months after cessation of treatment. In seven cases (38%), no or little (<20%) reduction in seizure frequency was observed 3 months after termination of treatment with ACTH. Reduction in seizure frequency after ACTH therapy was shown in Table 3 . Before treatment, all of the patients had severely abnormal EEG with most of tracing being covered by epileptic discharges. Repeat EEG 3 months after the end of treatment demonstrated more than 50% reduction of epileptic discharge in 16 of 25 (64%) cases. In this study, there was no relationship between response to ACTH and baseline variables including age, brain MRI, underlying disease and developmental status (P>0.05). Side effects of ACTH therapy including severe irritability, edema and weight gain with frequencies of 52%, 71%, and 61% were observed respectively ( Table  4) . Recurrence of seizure was reported before the next dose of ACTH during period of weekly injections in three cases with moderate initial response.
Discussion
ACTH is considered as one of the most effective available agents in controlling of intractable seizure (5, 7, 14 We observed frequent side effects including irritability, edema and weight gain in most of our patients but in no cases, a serious problem was observed. In cases with probable side effects, complete clinical and laboratory evaluation was performed and after rule out of serious side effects, treatment was continued. Similar side effects have been reported in previous studies in which ACTH has been used (4, 8) .
In our study, in no patient, seizure frequency increased, but recurrence of seizures, though with less frequency, was observed in three of the cases with moderate initial response before next dose of weekly ACTH injections. For treatment purpose in these cases, injection interval decreased to 5 d with good result. Because of high frequency of mentioned side effects, which causes severe concern and anxiety in patient's family and may finally end to premature cessation of treatment, we recommend that hospitalization of all patients for a period of 10-14 d at the onset of treatment and a close follow up of the patients be considered during treatment period. In our study, we have not performed video EEG monitoring in most of our patients so we could not exactly determine all seizure types in the patients. In 
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